Business
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., February 25, 2026--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025.
About this update from Decipher Labs Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4609,"height":986,"url":"https://media.zenfs.com/en/business-wire.com/289f08cc29401a85feae6437803b6986"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TNZwzsojnoA3lahbli1zbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/289f08cc29401a85feae6437803b6986","width":960,"height":205},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/i.pS143_IfKUNuztce6lzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/289f08cc29401a85feae6437803b6986","width":1200,"height":257}},"lazy":false},{"type":"text","content":"Grew fourth quarter total revenue to $140.6 million, an increase of 19%Grew fourth quarter testing revenue to $135.8 million, an increase of 21%","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call and webcast today at 4:30 p.m. ET","length":49,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., February 25, 2026--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025.","length":229,"tagName":"p"},{"type":"text","content":""We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter," said Marc Stapley, Veracyte’s chief executive officer. "We are achieving this growth while maintaining best-in-class profitability, with more than $50 million of cash generated from operations in the quarter. Looking ahead, 2026 will be an exciting year as we launch Prosigna as an LDT and TrueMRD, expanding our reach to more patients across the continuum of care while also continuing to invest in clinical evidence that reinforces the value and utility of our portfolio."","length":688,"tagName":"p"},{"type":"text","content":"Key Fourth Quarter 2025 Financial Highlights","length":44,"tagName":"p"},{"type":"text","content":"For the three-month period ended December 31, 2025, as compared to the same period in 2024:","length":91,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","...